Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets (2022 - 2025)

Historic Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $300.0 million.

  • Taysha Gene Therapies' Current Assets rose 8566.49% to $300.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.0 million, marking a year-over-year increase of 8566.49%. This contributed to the annual value of $142.1 million for FY2024, which is 516.32% down from last year.
  • Taysha Gene Therapies' Current Assets amounted to $300.0 million in Q3 2025, which was up 8566.49% from $316.3 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Current Assets registered a high of $316.3 million during Q2 2025, and its lowest value of $43.0 million during Q3 2022.
  • For the 4-year period, Taysha Gene Therapies' Current Assets averaged around $141.4 million, with its median value being $130.6 million (2024).
  • Data for Taysha Gene Therapies' Current Assets shows a peak YoY increase of 29953.26% (in 2023) and a maximum YoY decrease of 3230.67% (in 2023) over the last 5 years.
  • Over the past 4 years, Taysha Gene Therapies' Current Assets (Quarter) stood at $96.4 million in 2022, then skyrocketed by 55.44% to $149.9 million in 2023, then decreased by 5.16% to $142.1 million in 2024, then skyrocketed by 111.04% to $300.0 million in 2025.
  • Its Current Assets stands at $300.0 million for Q3 2025, versus $316.3 million for Q2 2025 and $120.7 million for Q1 2025.